Skip to content

MRS-based NAD+ quantification: Responsibility of a novel MRS-based method quantifying NAD+ in vivo

MRS-based NAD+ quantification: Responsibility of a novel MRS-based method quantifying NAD+ in vivo - NAD+ quantification with MRS

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON49618
Enrollment
20
Registered
2019-10-30
Start date
2020-07-09
Completion date
Unknown
Last updated
2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes insulin resistance

Interventions

ischemia (8 minutes) and prolonged fasting (36h)

Sponsors

Universiteit Maastricht
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Age: 18-40 years - BMI: 18-25 kg/m2 - Generally healthy

Exclusion criteria

Exclusion criteria: - regular (every day more than three cigarettes) smoking Par-ticipants who smoke by occasion (for instance during a party) but not daily are not ex-cluded from participation - Alcohol consumption (men > 4 units per day; women > 3 units per day) - Use of anti-coagulants or other medication known to hamper blood coagulation - Contraindications for MRI scans - Participation in other (intervention) studies - Subjects who do not want be informed about unexpected medical findings, or do not wish that their physician be informed cannot participate in the study - Any condition, disease, abnormal laboratory test result or medication that, in the opinion of the investigator and the dependent physician, would interfere with the study outcome, affect trial participation or put the subject at undue risk.

Design outcomes

Primary

MeasureTime frame
NAD+ concentration as measured by 31P-MRS before/after intervention.

Secondary

MeasureTime frame
Secondary endpoint is NAD+ as determined in muscle biopsies.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)